Manufacturer of tucatinib

Tucatinib is an anti-cancer drug used to treat HER2-positive breast cancer. It is a small molecule inhibitor of HER2. Tucatinib is developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly Oncothyreon and later part of Seattle Genetics), in 2023 the U.S. Food and Drug Administration (FDA) received accelerated approval of tucatinib in combination with trastuzumab for the treatment of patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer.

Common side effects of tucatinib include diarrhea, palmar-plantar paresthesia (burning or tingling sensation in the hands and feet), nausea, fatigue, hepatotoxicity (liver damage), vomiting, stomatitis, decreased appetite, abdominal pain, headache, anemia, and rash, which may cause harm to the developing fetus or baby. Tucatinib treatment can continue as long as the cancer does not progress and the side effects of the drug are tolerable.

It is understood that the original drug Tucatinib has not yet been launched in China, so it has not entered the scope of domestic medical insurance. Patients in need cannot yet purchase this drug in pharmacies or hospitals. The price of the European version of tucatinib original drug sold overseas is around RMB 72,000 (the price may fluctuate due to exchange rates), which is expensive. There are also generic drugs of tucatinib produced in other countries. The price of Tucatinib produced by a Lao pharmaceutical factory is around 6,400 yuan (the price may fluctuate due to the exchange rate). The price is much cheaper than the original drug, and the ingredients of foreign generic drugs are basically the same as the original drug.